Over 12 million people suffer from corneal blindness worldwide, as there is a huge shortage of corneal tissue transplants. StemSight’s aim is to make spare parts for the cornea that don’t rely on donor tissue.
StemSight’s first target indication is limbal stem cell deficiency (LSCD), a severe rare disease of the cornea currently without valid treatment options for patients suffering from LSCD in both eyes. StemSight’s off-the-shelf stem cell product could provide these patients with a cure to regain their vision. In the future, we aim to use the same stem cells to make other types of corneal cells, so that we can help patients suffering from other forms of blindness, such as corneal endothelial dystrophies.